Abstract
In the last 50 years there has been significant improvement in survival for children with cancer, achieved by the implementation of cooperative clinical research trials that found an opportunity to standardize and to control treatment of childhood cancer. Combined modalities in treatment approaches, intensification of chemotherapy regimens for high-risk disease allow to reach 70 % survival rate of all cases. Yet there is still a need to improve outcomes and decrease side effects of anticancer treatment in groups of unfavorable prognosis. The most promising point is personification of treatment with a special focus on targeted drug therapies and immunotherapy. We reviewed recent international advances and unique options in precision medicine for pediatric cancers.
Highlights
We reviewed recent international advances and unique options in precision medicine for pediatric cancers
Glade Bender J.L., Lee A., Reid J.M., Baruchel S., Roberts T., Voss S.D., Wu B., Ahern C.H., Ingle A.M., Harris P., Weigel B.J., Blaney S.M. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report
Summary
(Med.), Head of the Laboratory of Pediatric Neuro-Immuno-Oncology of the Pesonalized Medicine Centre and Head of the Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children at the Almazov National Medical Research Center, Ministry of Health of Russia, e-mail: dinikinayulia@mail.ru; https://orcid.org/0000-0002-2003-0982, SPIN-code: 1776-6462 M.B. Belogurova: Dr of Sci. При этом внедрение в практику препаратов направленной терапии принципиально изменяет возможности лечения многих онкологических заболеваний, а также профиль токсичности, в том числе у детей [11].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Russian Journal of Pediatric Hematology and Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
